Evaluating the Effect of 8-Week Treatment With Risperidone On Fasting Blood Glucose of Patients with Schizophrenia
,
Abstract
Objective: This study was designed to evaluate the effects of risperidone on fasting blood glucose (FBG) in patients with Schizophrenia .
Method: Seventy five non-diabetic patients with Schizophrenia (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) entered this cross-sectional study. Patients did not receive any medications (Including risperidone) affecting serum FBG levels for at least 2 weeks prior to the initiation of the study. Patients received the mean dose of 4.5mg (range 2-12mg) risperidone for 8 weeks. Pregnant women, patients with diabetes mellitus and a history of any major heart disease were excluded from this study.Additionally, none of the patients should have received electroconvulsive therapy within 6 months prior to the initiation of the antiphsychotics.FBG levels were measured at the initiation and 8 weeks after starting risperidone.
Results: Fifty one patients completed the study. The mean FBG level was increased from 88.9mg/dL (baseline) to 94.4 mg/dL at week 8 (P =0.003). This 8-week study showed that FBG levels may increase in schizophrenic patients receiving risperidone.
Conclusion: Measuring and monitoring FBG before the initiation and during the treatment with risperidone is suggested.
Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 2000; 321: 1371-1376.
Tran PV, Dellva MA, Tollefson GD, Beasley CM ,Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58: 205-211.
Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang R, Nasrallah HA. Differential Effects of Risperidone, Olanzapine, Clozapine, and Conventional Antipsychotics on Type 2 Diabetes: Findings From a Large Health Plan Database. J Clin Psychiatry 2002; 63: 920- 930.
Jin H, Meyer JM, Jeste DV. Phenomenology of and Risk Factors for New-Onset Diabetes Mellitus and Diabetic Ketoacidosis Associated with Atypical Antipsychotics: An Analysis of 45 Published Cases. Ann Clin Psychiatry 2002; 14: 59-64.
Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med 2001; 111: 716-723.
Koller EA, Doraiswamy PM. Olanzapine- Associated Diabetes Mellitus. Pharmacotherapy 2002; 22: 841-852.
Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J ,et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br Med J 2002; 325: 243.
Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine Use in Patients With Schizophrenia and the Risk of Diabetes, Hyperlipidemia, and Hypertension A Claims-Based Approach. Arch Gen Psychiatry; 2001; 58: 1172-1176.
Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone-and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63: 425-433.
Mohan D, Gordon H, Hindley N, Barker A. Schizophrenia and diabetes mellitus. Br J Psychiatry Suppl 1999; 174: 180b.
Sernyak MJ ,Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of Schizophrenia. Am J Psychiatry 2002; 159: 561-566.
Wirshing DA, Wirshing WC, Kysar L, Berisford MA ,Goldstein D, Pashdag J, et al. Novel antipsychotics: Comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358-363.
Koller EA, Cross JT, Doraiswamy PM, Malozowski SN. Pancreatitis Associated with Atypical Antipsychotics :From the Food and Drug Administration’s MedWatch Surveillance System and Published Reports. Pharmacotherapy 2003; 23: 1123-1130.
Chue P. The Assessment and Management of Antipsychotic-Associated Metabolic Disturbances from a Psychiatric Perspective. Can J Psychiatry 2004; 49: 200-207.
Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics. Am J Psychiatry 2003; 160: 290-296.
| Files | ||
| Issue | Vol 2 No 3 (2007) | |
| Section | Articles | |
| Keywords | ||
| Blood glucose Risperidone Schizophrenia | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
